Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
77557.180.3621%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Faeth Therapeutics Inc

FTHNASDAQ
Trade with Public
Trade with Public
$33.84
0.100.3%
At close: Aug 28, 5:00 PM EST
$33.84
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Faeth Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Faeth Therapeutics (FTH).

Price Target Range — 2 Quarters

Analyst Consensus — 8 Analysts

1S.Buy
7Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$56Upside to Avg. PT+66.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026NeedhamGil BlumInitiateBuy$56
Aug 11, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$60
More with Benzinga EdgeGet Access

Analyst Ratings News

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Avi Kapoor

PRO
Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56

Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
Benzinga Newsdesk

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
Avi Kapoor

This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
Avi Kapoor

PRO
Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved